These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Padmore R Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898 [TBL] [Abstract][Full Text] [Related]
3. The role of inflammation in intravenous immune globulin-mediated hemolysis. Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900 [TBL] [Abstract][Full Text] [Related]
4. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis. Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR; Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931 [TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904 [TBL] [Abstract][Full Text] [Related]
6. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896 [TBL] [Abstract][Full Text] [Related]
7. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. Taylor E; Vu D; Legare C; Keene D Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894 [TBL] [Abstract][Full Text] [Related]
8. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial. Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067 [TBL] [Abstract][Full Text] [Related]
9. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176 [TBL] [Abstract][Full Text] [Related]
10. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin? Zimring JC Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903 [TBL] [Abstract][Full Text] [Related]
11. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910 [TBL] [Abstract][Full Text] [Related]
12. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale. Thorpe SJ Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902 [TBL] [Abstract][Full Text] [Related]
13. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients. Duronio A; Bajjoka I; Hsaiky L; Parasuraman R Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157 [TBL] [Abstract][Full Text] [Related]
14. Not all intravenous immunoglobulin preparations are equally well tolerated. Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625 [TBL] [Abstract][Full Text] [Related]
15. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease. Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654 [TBL] [Abstract][Full Text] [Related]
16. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192 [TBL] [Abstract][Full Text] [Related]
17. Anti-A and anti-B: what are they and where do they come from? Branch DR Transfusion; 2015 Jul; 55 Suppl 2():S74-9. PubMed ID: 26174901 [TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and mechanisms of antibody-mediated hemolysis. Flegel WA Transfusion; 2015 Jul; 55 Suppl 2(0):S47-58. PubMed ID: 26174897 [TBL] [Abstract][Full Text] [Related]
19. Maternal hemolysis after intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia. Rink BD; Gonik B; Chmait RH; O'Shaughnessy R Obstet Gynecol; 2013 Feb; 121(2 Pt 2 Suppl 1):471-3. PubMed ID: 23344412 [TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome. Lin WL; Lin WC; Chang YC; Yang LC; Hung SI; Hong HS; Chung WH Am J Clin Dermatol; 2009; 10(5):339-42. PubMed ID: 19658448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]